Anti-Coagulants - EMEA

EMEA

Revenue in the Anti-Coagulants market is projected to reach US$6.91bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 7.65%, resulting in a market volume of US$9.28bn by 2028.
In global comparison, most revenue will be generated in the United States (US$16,740.00m in 2024).

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

In the past years, the revenue in the Anti-Coagulants market has experienced strong growth, mainly driven by a strong increase in sales of direct oral anti-coagulants. While this trend is expected to continue for the next few years, a substantial decline is projected for the last years of the forecast period. This can be explained by expiring patents, e.g., in the case of Xarelto in the European Union (in 2023) and in the U.S. (in 2024) or in the case of Eliquis in 2026, which will result in the expected drop in each of these years.

Since the start of the COVID-19 pandemic, limited access to healthcare facilities has triggered a shift away from warfarin, which requires monitoring, and injectables. Instead, more oral anti-coagulants have been used, compensating the negative impact of the pandemic and leading to notable growth in 2020.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.